Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
  • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
  • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/67—Vitamins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants

Definitions

• the present invention relates to an oral composition.
• Periodontal disease is an infection caused by bacteria, mainly anaerobic gram-negative bacteria such as Porphyromonas gingivalis, and exotoxins (leucotoxins, etc.) and endotoxins (lipopolysaccharides, etc.) produced by the bacteria. ) Induces inflammation and damages the tissue. Therefore, the development of bactericides and antibacterial agents has been promoted in order to eliminate periodontal pathogenic bacteria.
• neutrophils and lymphocytes infiltrate the periodontal pockets and gingival tissues, phagocytose periodontopathic bacteria, and produce an immune response that eliminates these foreign substances by creating specific antibodies.
• active oxygen excessively generated during phagocytosis further damages living tissues and causes periodontal disease to progress.
• toxins remain even after periodontopathic bacteria die, and inflammation caused by the toxins continues to produce new active oxygen.
• environmental factors such as smoking and stress have been reported to increase active oxygen.
• Bactericides and antibacterial agents are desirable to have “immediate effects” that immediately exert their effects.
• active oxygen changes depending on chemical reactions such as hydrogen peroxide, hydroxy radicals, superoxide, etc., and continues as inflammation progresses. Produced. Therefore, in order to remove these active oxygen species, “long-lasting” is desirable in addition to “high removal effect”.
• antioxidant for example, ascorbic acid phosphate, which is a derivative of ascorbic acid, is more stable than ascorbate and suppresses inflammation by eliminating excess active oxygen produced in the body. Effects have been reported, and application technologies to oral compositions such as toothpastes and lozenges (Patent Document 1) and techniques for improving mucosal absorbability using a cationic polymer in combination (Patent Document 2) are being studied.
• Vitamin E and its derivatives known as fat-soluble antioxidants, are commonly used as antioxidants for foods and pharmaceuticals (Patent Document 3), and are also used to improve retention by hydrogel particles (Patent Document 4).
• Etc. have been proposed. Astaxanthin and fucoxanthin are also antioxidants that attract attention due to their high effects. They are blended into pharmaceutical compositions (Patent Document 5), sunburn and blotch reduction techniques (Patent Document 6), and ingested in the blood by food intake. A technique for reducing active oxygen (Patent Document 7) and the like have been proposed.
• This invention is made
• the present inventors have used reactive lactam compounds in combination with antioxidants to reduce the active oxygen in gingival constituent cells even in an environment where saliva flow is assumed. It has been found that it can be erased for a long time, and the present invention has been completed.
• the present invention provides the following [1] to [5].
• [1] A lactam compound having an acidic group selected from the group consisting of pyrrolidonecarboxylic acid, 6-oxo-2-piperidinecarboxylic acid, and 3- (2-oxo-1-azepanyl) propanoic acid and / or a salt thereof
• (B) composition for oral cavity containing antioxidant substance [2] The composition for oral cavity according to [1], wherein the component (A) is pyrrolidonecarboxylic acid and / or a salt thereof.
• the component (B) is one or more antioxidants selected from the group consisting of ascorbic acid and its derivatives, vitamin E and its derivatives, astaxanthin, and fucoxanthin, according to [1] or [2] Oral composition.
• B an active oxygen scavenger containing an antioxidant as an active ingredient.
• an oral composition having a high periodontal disease prevention effect by erasing the active oxygen in the cells constituting the gingiva for a long time.
• composition for oral cavity of the present invention comprises (A) a lactam having an acidic group selected from the group consisting of pyrrolidonecarboxylic acid, 6-oxo-2-piperidinecarboxylic acid, and 3- (2-oxo-1-azepanyl) propanoic acid. A compound and / or a salt thereof, and (B) an antioxidant.
• the component (A) contained in the oral composition of the present invention is selected from the group consisting of pyrrolidonecarboxylic acid, 6-oxo-2-piperidinecarboxylic acid, and 3- (2-oxo-1-azepanyl) propanoic acid.
• the active oxygen in the cells constituting the gingiva can be erased for a long period of time, thereby preventing periodontal disease.
• the composition for oral cavity which has this is implement
• the salt is not particularly limited as long as it is a pharmacologically acceptable salt.
• pharmacologically acceptable salts include acid addition salts, base addition salts, and amino acid salts. Specific examples thereof include inorganic acid salts such as hydrochloride, hydrobromide, sulfate, hydroiodide, nitrate, phosphate; citrate, oxalate, acetate, formate, propion Acid salt, benzoate salt, trifluoroacetate salt, maleate salt, tartrate salt, methanesulfonate salt, benzenesulfonate salt, paratoluenesulfonate salt, etc .; sodium salt, potassium salt, calcium salt, magnesium Inorganic base salts such as salts and ammonium salts; organic base salts such as triethylammonium salt, triethanolammonium salt, pyridinium salt and diisopropylammonium salt; and
• the component (A) is particularly preferably pyrrolidone carboxylic acid and / or a salt thereof.
• the lactam compound or salt thereof used as the component (A) can be synthesized according to a known scheme. Or the lactam compound used as (A) component or its salt may use a commercial item.
• Examples of commercially available products of pyrrolidone carboxylic acid include “AJIDEW A-100 (registered trademark)” sold by Ajinomoto Co., Inc.
• Examples of commercially available sodium pyrrolidone carboxylate include “AJIDEW NL-50 (registered trademark)” sold by Ajinomoto Co., Inc.
• 6-oxo-2-piperidinecarboxylic acid examples include “(S) -6-Oxo-2-piperidinecarboxylic acid (trade name)” sold by Sigma Aldrich Japan Co., Ltd.
• 3- (2-oxo-1-azepanyl) propanoic acid examples include “3- (2-Oxoazepan-1-yl) propanoic acid (trade name)” sold by Sigma Aldrich Japan Co., Ltd. Is mentioned.
• the component (A) may be used alone or in combination of two or more.
• the content of the component (A) in the oral composition of the present invention is preferably 0.1% by mass or more and 0.5% by mass or more from the viewpoint of enhancing the sustainability of the active oxygen scavenging effect. Is more preferable, and it is further more preferable that it is 1 mass% or more.
• the upper limit of the content of the component (A) in the oral composition of the present invention is preferably 10% by mass or less, and preferably 5% by mass or less from the viewpoints of sustainability of the active oxygen scavenging effect and formulation stability. It is more preferable.
• the content of the component (A) in the oral composition of the present invention is preferably 0.1 to 10% by mass, and 0.5 to 5% by mass with respect to the total amount of the oral composition. %, More preferably 1 to 5% by mass.
• content of each component in a composition for oral cavity is based on the preparation amount of each component at the time of manufacturing a composition.
• ⁇ (B) component> (B) component contained in the composition for oral cavity of this invention is an antioxidant substance.
• antioxidants that can be suitably used as the component (B) include ascorbic acid and derivatives thereof, vitamin E and derivatives thereof, astaxanthin, fucoxanthin, glutathione, uric acid, ⁇ -carotene, vitamin A, ubiquinol, and flavonoids.
• ascorbic acid derivatives include, for example, ascorbic acid phosphate salts such as magnesium ascorbic acid phosphate and sodium ascorbic acid phosphate.
• vitamin E derivatives include tocopherol acetate and tocopherol nicotinate.
• the component (B) is selected from the group consisting of ascorbic acid and its derivatives, vitamin E and its derivatives, astaxanthin, and fucoxanthin.
• One or more antioxidants selected are preferable, one or more antioxidants selected from the group consisting of ascorbic acid phosphate, vitamin E and its derivatives, astaxanthin, and fucoxanthin are more preferable, and ascorbic acid phosphate
• One or more antioxidants selected from the group consisting of salts and vitamin E and derivatives thereof are more preferable, and one or more antioxidants selected from the group consisting of magnesium ascorbate phosphate and tocopherol acetate are particularly preferable.
• the antioxidant used as the component (B) can be synthesized according to a known scheme. Alternatively, a commercially available product may be used as the antioxidant used as component (B).
• the component (B) may be used alone or in combination of two or more.
• the content of the component (B) in the oral composition of the present invention is preferably 0.01% by mass or more, more preferably 0.05% by mass or more, from the viewpoint of enhancing the sustainability of the active oxygen scavenging effect. More preferably, the content is 0.1% by mass or more.
• the upper limit of the content of the component (B) in the oral composition of the present invention is preferably 2% by mass or less, more preferably 1% by mass or less from the viewpoint of formulation stability.
• the content of the component (B) in the oral composition of the present invention is preferably 0.01 to 2% by mass, and 0.05 to 1% by mass with respect to the total amount of the oral composition. % Is more preferable, and 0.1 to 1% by mass is even more preferable.
• the mass ratio of the component (A) to the component (B) [(A) component / (B) component] in the oral composition of the present invention is preferably 1 or more. More preferably, it is 2 or more.
• the mass ratio of the (A) component to the (B) component [(A) component / (B) component] in the oral cavity composition of the present invention is 100 or less. It is preferable that it is 30 or less. In order to achieve both the sustainability of the active oxygen scavenging effect and the formulation stability at a high level, it is preferably 1 to 100, more preferably 2 to 30.
• the shape and dosage form of the oral composition of the present invention are not particularly limited.
• it can be prepared in various shapes such as a liquid system (liquid, liquid, paste) and a solid system (solid, solid).
• dosage forms include toothpaste compositions such as toothpaste, liquid dentifrice, liquid dentifrice, powder dentifrice, mouthwash composition, coating composition, oral pasta, mouth freshener composition, food form (for example, Chewing gum, tablet confectionery, candy, gummi, film, troche, etc.).
• the oral composition of the present invention contains a known additive component (pharmacologically acceptable carrier) that can be used for the oral composition within a range not impairing the effects of the present invention.
• a known additive component pharmaceutically acceptable carrier
• additional components include abrasives, binders, thickeners, surfactants, sweeteners, preservatives, fragrances, medicinal ingredients, colorants, brighteners, pH adjusters, solvents, excipients. And can be appropriately selected depending on the dosage form.
• the specific example of an additional component is shown below, the component which can be mix
• abrasive examples include silica-based abrasives such as silicic anhydride, crystalline silica, amorphous silica, silica gel, aluminosilicate, zeolite, calcium hydrogen phosphate anhydrous, calcium hydrogen phosphate dihydrate, Examples thereof include calcium pyrophosphate, calcium carbonate, aluminum hydroxide, alumina, magnesium carbonate, tribasic magnesium phosphate, zirconium silicate, tertiary calcium phosphate, hydroxyapatite, tetracalcium phosphate, and a synthetic resin abrasive.
• silica-based abrasives such as silicic anhydride, crystalline silica, amorphous silica, silica gel, aluminosilicate, zeolite, calcium hydrogen phosphate anhydrous, calcium hydrogen phosphate dihydrate
• examples thereof include calcium pyrophosphate, calcium carbonate, aluminum hydroxide, alumina, magnesium carbonate, tri
• Abrasives can be used singly or in combination of two or more.
• the blending amount of the dentifrice is preferably 2 to 40% by mass, more preferably 5 to 20% by mass of the entire composition.
• the mouthwash it is preferably 0 to 10% by mass, more preferably 0 to 5% by mass, based on the entire composition.
• binder examples include pullulan, gelatin, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, carrageenan, sodium alginate, xanthan gum, sodium polyacrylate, gum arabic, guar gum, locust bean gum, polyvinyl alcohol, polyvinyl Examples include pyrrolidone and carboxyvinyl polymer.
• a binder can be used individually by 1 type or in combination of 2 or more types. The amount of the binder used is usually 0.01 to 3% by mass with respect to the whole composition.
• thickening agent examples include sorbitol, propylene glycol, butylene glycol, glycerin, polyethylene glycol and the like.
• a thickener can be used individually by 1 type or in combination of 2 or more types. When a thickener is used, the amount of the thickener can be determined within a range not impeding the effects of the present invention, and is usually 1 to 60% by mass with respect to the entire composition.
• surfactant examples include an anionic surfactant and a nonionic surfactant.
• anionic surfactant examples include N-acyl amino acid salts, ⁇ -olefin sulfonates, N-acyl sulfonates, alkyl sulfates, glycerol fatty acid ester sulfates, and the like.
• N-acylamino acid salts, ⁇ -olefin sulfonates, alkyl sulfates, and the like are preferable from the viewpoint of versatility, and lauroyl sarcosine sodium, alkyl chain carbon chain length from the viewpoint of foamability and hard water resistance. More preferred are sodium ⁇ -olefin sulfonates having 10 to 16 carbon atoms, sodium lauryl sulfate, and the like.
• Nonionic surfactants include, for example, polyoxyethylene alkyl ether, polyoxyethylene-polyoxypropylene block copolymer, polyoxyethylene hydrogenated castor oil, glycerin ester polyoxyethylene ether, sucrose fatty acid ester, alkylolamide And glycerin fatty acid ester.
• polyoxyethylene alkyl ether, polyoxyethylene hydrogenated castor oil, alkylolamide, sorbitan fatty acid ester and the like are preferably used from the viewpoint of versatility.
• the carbon chain length of the alkyl chain is preferably 14 to 18 carbon atoms.
• the polyoxyethylene alkyl ether preferably has an average addition mole number of ethylene oxide of 15 to 30.
• the polyoxyethylene hydrogenated castor oil preferably has an average ethylene oxide addition mole number (average addition EO) of 20 to 100.
• the alkyl chain preferably has a carbon chain length of 12 to 14 carbon atoms.
• the sorbitan fatty acid ester preferably has 12 to 18 carbon atoms in the fatty acid.
• the polyoxyethylene sorbitan fatty acid ester preferably has 16 to 18 carbon atoms in the fatty acid.
• the polyoxyethylene sorbitan fatty acid ester preferably has an average ethylene oxide addition mole number of 10 to 40.
• Surfactants can be used alone or in combination of two or more.
• the blending amount is usually 0 to 10% by mass and preferably 0.01 to 5% by mass with respect to the whole composition.
• sweetening agent examples include saccharin sodium, stevioside, neohesperidin hydrochalcone, glycyrrhizin, perilartin, p-methoxycinnamic aldehyde, thaumatin, palatinose, maltitol, xylitol, arabitol and the like.
• a sweetener can be used individually by 1 type or in combination of 2 or more types. When a sweetener is used, the blending amount can be appropriately determined within a range not impairing the effects of the present invention.
• preservative examples include paraoxybenzoic acid esters such as sodium benzoate, methylparaben, ethylparaben, and butylparaben, ethylenediaminetetraacetate, benzalkonium chloride, and the like.
• a preservative can be used individually by 1 type or in combination of 2 or more types. When the preservative is used, the blending amount can be appropriately determined within a range not impairing the effects of the present invention.
• fragrances examples include natural fragrances, synthetic fragrances (single fragrances), blended fragrances (oil and fat fragrances (oil-based fragrances), powdered fragrances, etc.).
• flavor can be used individually by 1 type or in combination of 2 or more types.
• natural flavors include mastic oil, parsley oil, anise oil, eucalyptus oil, winter green oil, cassia oil, menthol oil, spearmint oil, peppermint oil, lemon oil, coriander oil, orange oil, mandarin oil, lime oil.
• Single flavors include, for example, carvone, anethole, methyl salicylate, cinnamaldehyde, linalool, linalyl acetate, limonene, menthone, menthyl acetate, pinene, octyl aldehyde, citral, pregon, carbyl acetate, anisaldehyde, ethyl acetate, ethyl butyrate Rate, allylcyclohexanepropionate, methylanthranilate, ethylmethylanthranilate, vanillin, undecalactone (such as ⁇ -undecalactone, ⁇ -undecalactone), hexanal (such as trans-2-hexenal), ethi Non-alcohol, propyl alcohol, butanol, isoamyl alcohol, hexenol (cis-3-hexenol etc.), dimethylsulfide, cycloten
• Single flavors include menthol, N-ethyl-p-menthane-3-carboxamide, N- (ethoxycarbonylmethyl) -3-p-menthane carboxamide, N, 2,3-trimethyl-2-isopropylbutanamide , 3- (L-methoxy) propane-1,2-diol, menthyl lactate (menthyl lactate), monomenthyl succinate, menthone glycerol acetal, 3-l-menthoxypropane-1,2-diol, menthose glycerol ether, spiranthol And monomenthyl succinate.
• the blended fragrance is a fragrance made by blending a single fragrance and / or a natural fragrance.
• Examples include menthol micron, strawberry flavor, apple flavor, banana flavor, pineapple flavor, grape flavor, mango flavor, tropical fruit flavor, butter flavor, milk flavor, yogurt flavor, fruit mix flavor, herbal mint flavor and the like.
• the form of the fragrance is not limited, and any of essential oils, extracts, solids, and powders obtained by spray drying any of these may be used.
• the above fragrance material is preferably used in an amount of 0.000001 to 1% by mass in the preparation composition.
• the flavoring fragrance using the fragrance material is preferably used in an amount of 0.1 to 2.0% by mass in the preparation composition.
• the medicinal component examples include the following components: bactericidal or antibacterial agents such as chlorohexidine, triclosan, isopropylmethylphenol, cetylpyridinium chloride, zinc gluconate, zinc citrate; condensed phosphate, ethane hydroxydiphosphonate Anti-inflammatory agents such as tranexamic acid, glycyrrhizic acid dipotassium salt, ⁇ -aminocaproic acid, and apricot extract; coating agents such as hydroxyethylcellulose dimethyldiallylammonium chloride; allantochlorhydroxyaluminum, vitamin C, lysozyme chloride, Astringents such as glycyrrhetinic acid and its salts, sodium chloride and allantoin; hypersensitivity inhibitors such as strontium chloride.
• the compounding amount in the case of using a medicinal component can be appropriately set within a pharmaceutically acceptable range for each medicinal component.
• the colorant examples include natural pigments such as safflower red pigment, gardenia yellow pigment, gardenia blue pigment, perilla pigment, sockeye pigment, red cabbage pigment, carrot pigment, hibiscus pigment, cacao pigment, spirulina pigment, and coumarindo pigment.
• the blending amount is preferably 0.00001 to 3% by mass with respect to the entire composition.
• the brightener examples include waxes such as shellac, carnauba wax and candelilla wax, calcium stearate, and the like.
• the blending amount is preferably 0.01 to 5% by mass with respect to the entire composition.
• the pH (20 ° C.) of the oral composition of the present invention is usually 6 to 10, preferably 6 to 9.
• the pH adjuster include acetic acid, hydrochloric acid, sulfuric acid, nitric acid, citric acid, phosphoric acid, malic acid, gluconic acid, maleic acid, succinic acid, glutamic acid, sodium hydroxide, potassium hydroxide, sodium acetate, sodium carbonate, Examples include acids and alkalis such as sodium citrate, sodium hydrogen citrate, sodium phosphate, and sodium dihydrogen phosphate, and buffers.
• the blending amount can be appropriately determined within a range not impairing the effects of the present invention.
• the solvent examples include water and lower alcohols having 3 or less carbon atoms such as ethanol and propanol.
• the solvent is usually blended in a liquid oral composition.
• the blending amount is preferably 20 to 95% by mass with respect to the entire composition.
• the blending amount is preferably 1 to 20% by mass with respect to the entire composition.
• excipients examples include syrup, glucose, fructose, invert sugar, dextrin, oligosaccharide and the like.
• an excipient is usually added.
• the excipient is blended, the blending amount can be appropriately determined within a range not impairing the effects of the present invention.
• the active oxygen scavenger of the present invention comprises (A) a lactam having an acidic group selected from the group consisting of pyrrolidonecarboxylic acid, 6-oxo-2-piperidinecarboxylic acid, and 3- (2-oxo-1-azepanyl) propanoic acid.
• a compound and / or a salt thereof and (B) an antioxidant are contained as active ingredients.
• the compounding ratio of the component (A) and the component (B) in the active oxygen scavenger of the present invention can be the same as the compounding ratio described in [Composition for oral cavity] above.
• the active oxygen targeted by the active oxygen scavenger of the present invention is not particularly limited.
• the active oxygen scavenger of the present invention is excellent in sustaining the active oxygen scavenging effect even in an environment where gingival environmental fluid such as saliva flows, and is used to remove active oxygen in gingival constituent cells. It is preferable to do.
• the administration form of the active oxygen scavenger of the present invention is not particularly limited.
• oral administration for example, oral administration, sublingual administration, etc.
• parenteral administration intravenous administration, intramuscular administration, subcutaneous administration, transdermal
• nasal administration pulmonary administration, etc.
• a less invasive dosage form is preferable, and oral administration or transdermal administration is more preferable.
• the subjects who take the active oxygen scavenger of the present invention are subjects who have already developed symptoms due to active oxygen (for example, periodontal tissue trouble (gingival recession, etc.)) Examples include subjects who have no symptoms but want to prevent.
• the administration time of the agent of the present invention is not particularly limited.
• Examples 1 to 37 and Comparative Examples 1 to 7 Using the components described above, oral compositions of Examples 1 to 37 and Comparative Examples 1 to 7 were prepared by the following preparation methods according to the blending ratios (parts by mass) shown in Tables 1 to 5. About the prepared oral composition, the sustainability of the active oxygen elimination effect and formulation stability were evaluated according to the following procedure. The evaluation results are shown in Tables 1-5.
• the pH of the obtained uniform liquid was adjusted to a range of 6 to 9 using a pH adjuster (hydrochloric acid or sodium hydroxide) to obtain an oral composition.
• the pH was measured using a pH meter (“HM-26S” manufactured by Toa Denpa Kogyo Co., Ltd.).
• the composition for oral cavity was used for various evaluations after sterilizing the filter (0.22 ⁇ m).
• the medium supernatant was removed, 0.5 mL of D-MEM medium containing no drug was added, and the mixture was incubated on a shaker (manufactured by Nippon Genetics) for 12 hours with stirring (5 rpm). After the incubation, the culture supernatant was removed, 0.5 mL of D-MEM medium containing no drug was added again, and the mixture was incubated for 12 hours on a shaker (manufactured by Nippon Genetics) with stirring (5 rpm). The culture supernatant was removed, 0.4 mL of D-MEM medium (containing 10 ⁇ M CM-H2DCFDA fluorescent reagent) was added and incubated for 30 minutes.
• the fluorescence intensity of the hydrogen peroxide-free group was subtracted from the actually measured fluorescence intensity of the control group and the fluorescence intensity of the examples and comparative examples.
• the value (that is, the value excluding the amount of active oxygen originally possessed by the cell for viability) was used.
• said evaluation test was implemented 3 times about each chemical
• Active oxygen erasure rate is 30% or more ⁇ : Active oxygen erasure rate is 20% or more and less than 30% ⁇ : Active oxygen erasure rate is 10% or more and less than 20% ⁇ : Active oxygen erasure rate is less than 10%
• compositions for oral cavity prepared in Examples and Comparative Examples were stored in a high temperature bath at 50 ° C. for 1 month.
• the oral composition after storage was visually confirmed, and the preparation stability (discoloration and occurrence of orientation) was evaluated based on the following evaluation criteria.
• composition for oral cavity of Comparative Examples 1 to 4 containing only the component (B) without containing the component (A) and the oral composition of Comparative Examples 5 to 7 containing only the component (A) without containing the component (B) All the compositions showed only a low active oxygen scavenging rate, and the sustainability of the active oxygen scavenging effect was insufficient.
• oral compositions of Examples 1 to 37 containing a combination of the component (A) and the component (B) exhibit a high active oxygen scavenging rate, are excellent in the sustainability of the active oxygen scavenging effect, and are stable in the preparation. It was confirmed that it was excellent.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Birds (AREA)
• Epidemiology (AREA)
• Chemical & Material Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Toxicology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Biochemistry (AREA)
• Cosmetics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=50684596

Family Applications (1)

Country Status (6)

Cited By (4)

Families Citing this family (4)

Citations (3)

Family Cites Families (14)

• 2013
  • 2013-11-01 JP JP2014545694A patent/JP6243849B2/ja active Active
  • 2013-11-01 WO PCT/JP2013/079743 patent/WO2014073490A1/ja active Application Filing
  • 2013-11-01 MY MYPI2015701224A patent/MY184460A/en unknown
  • 2013-11-01 KR KR1020157006259A patent/KR102076611B1/ko active IP Right Grant
  • 2013-11-01 CN CN201380058607.9A patent/CN104780901B/zh active Active
• 2015
  • 2015-04-16 PH PH12015500834A patent/PH12015500834A1/en unknown

Patent Citations (3)

Also Published As

Similar Documents

Legal Events